Card image cap
NAYA Biosciences Announces Publication of New Data for its CD38-targeted Flex-NK™ Bispecific Antibody in the American Society of Hematology’s Blood Journal

Abstract from 2023 American Society of Hematology (ASH) MeetingData demonstrates differentiated profile from DARZALEX

December 11, 2023
Card image cap
NAYA Biosciences and ONK Therapeutics Announce Research Partnership to Advance Combination Therapy of FLEX-NK™ Bispecific Antibodies and Optimally Engineered Off-the-Shelf Natural Killer Cell Therapies

NAYA Biosciences and ONK Therapeutics to assess proof-of-concept and establish activity and feasibility of the combinati

December 6, 2023
Card image cap
INVO Bioscience Regains Compliance with Nasdaq Minimum Stockholders’ Equity Requirement

SARASOTA, Fla., Nov. 28, 2023 -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a healthcare services

November 28, 2023
Card image cap
INVO Reports Record Third Quarter 2023 Financial Results

Company Expects to Host Conference Call Shortly After November 20, 2023 Following the Progress of Certain Closing Condit

November 13, 2023
Card image cap
NAYA Biosciences and INVO Bioscience Announce Appointment of Dr. Peter Kash, Ed.D., MBA as Vice Chairman Following Closing of Their Pending Merger

SARASOTA, Fla. and AVENTURA, Fla., Nov. 10, 2023 -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO"), a healthcare service

November 10, 2023
Card image cap
INVO Bioscience Announces Commencement of Waiver Solicitation From Holders of the Company’s Common Stock Purchase Warrants

SARASOTA, Fla., Nov. 9, 2023 -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a healthcare services c

November 9, 2023
Card image cap
Free Registration Is Now Open For Tribe Public’s CEO and Q&A Presentation Webinar Event “Accelerating Biotech Value Creation” Featuring NAYA Biosciences CEO Dr. Daniel Teper On Tuesday, October 31, 2023

An Introduction to NAYA Biosciences with CEO Dr. Daniel TeperManaging unprecedented medical innovation in an era of fina

October 27, 2023
Card image cap
INVO Bioscience and NAYA Biosciences Announce Definitive Merger Agreement To Establish Expanded Publicly Traded Life Science Company

Post-merger, the combined company, operating under the name "NAYA Biosciences", will be dedicated to increasing patient

October 23, 2023
Card image cap
INVO to Participate in the Lytham Partners Fall 2023 Investor Conference

SARASOTA, Fla., Oct. 11, 2023 -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a healthcare services

October 11, 2023